drugset / Trial / NCT05247996

TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

NCT05247996

Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional intravenous chemotherapy), to explore the efficacy and safety of TACE combined with multi-target drugs and PD-1 inhibitors as first-line treatment compared with traditional systemic intravenous chemotherapy in the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).

Timeline

Start
2022-03-01
Primary completion
2022-12-31
Completion
2023-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 0.2 g Oral
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous